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Abstract
Despite recent advances in developing and licensing adjuvants, there is a great need for more potent formulations to
enhance immunogenicity of vaccines. An Eimeria tenella derived antigen (rEA) augments immune responses against several
pathogens in animal models and recently was confirmed to be safe for human use. In this study, we have analyzed the
molecular mechanisms underlying rEA activity in mice, and confirmed that rEA activates multiple immune cell types,
including DCs, macrophages, NK, B, and T cells. The rEA adjuvant also elicits the induction of pleiotropic pro-inflammatory
cytokines, responses that completely depend upon the presence of the TLR adaptor protein MyD88. Surprisingly, we also
found that the TRIF adaptor protein acts as a potent negative regulator of TLR agonist-triggered immune responses. For
example, IL12 production and the induction of co-stimulatory molecule expression by DCs and IFNc production by NK cells
in vivo were significantly increased in rEA-treated TRIF-KO mice. Importantly, however, TRIF suppressive effects were not
restricted to rEA-mediated responses, but were apparent in LPS- or ODN2006-activated DCs as well. Taken together, our
findings confirm that rEA is a potent adjuvant, triggering robust activation of the innate immune system, in a manner that is
augmented by MyD88 and inhibited by TRIF; thereby unveiling the potential complexities of modulating TLR activity to
augment vaccine efficacy.
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Introduction
There is a great need to develop more efficient vaccines to
combat or prevent infections by a number of detrimental
pathogens that continue to plague mankind [1,2,3]. The use of
novel adjuvants capable of beneficially stimulating the immune
system to maximize efficacy of various vaccination strategies is a
rapidly developing field. Most adjuvants augment the induction of
innate immune responses by triggering robust activation of
dendritic cells (DCs) and macrophages, actions that can result in
improved induction of antigen specific adaptive immune respons-
es. Upon migration to the draining lymph nodes, these highly
active antigen presenting cells (APCs) are capable of presenting
specific antigens to responsive T cells, thereby generating
significant pools of antigen-specific T cells [2,4]. Incorporation
of Toll-like receptor (TLR) ligands into vaccine formulations
represent a class of adjuvants proposed for usage in next
generation vaccines. This is primarily due to TLRs being
expressed at high levels on important immune cell types (DCs,
macrophages, NK cells) and their ability to potently activate the
innate immune system [4,5,6].
In light of these facts, the recombinant, Eimeria tenella derived
antigen (rEA) has been proven to be capable of inducing IL-12p70
production, enhancing Th1 cellular responses, and yielding
protection against Toxoplasma gondii infection in mice [7]. rEA
has also been shown to be an efficient immunomodulator, having
both antiviral and anti-cancer properties [8,9,10]. Previous studies
have also shown that HIV-gag-specific T cell responses are
significantly increased when rEA formulations are administered
together with the antigen [11,12]. Moreover, rEA showed no
evidence of toxicity in pre-clinical [8] and clinical trials [13].
Specifically, no severe adverse reactions were reported in human
clinical trials despite detection of increased IL-12 responses in 30%
of the treated cancer patients [13].
The rEA protein has a relatively high amino acid sequence
homology (67%) and shares very similar biological activities in vitro
and in vivo with T. gondii-derived profilin-like protein, both of which
trigger potent IL-12 responses in DCs. The profilin induced
responses were completely dependent upon the adaptor protein
MyD88 and at least partially mediated via TLR11 [14].
Moreover, it has been shown in vitro that human TLRs (TLR2,
TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9) do not transduce
rEA signaling [9]. Therefore, TLR11 has been suggested as the
rEA receptor mediating rEA signaling, but this notion remains to
be confirmed. Since no functional human TLR11 homolog has
been discovered, these facts leave unidentified the mechanism
underlying rEA action in humans, and opens a discussion
regarding other pattern recognition receptors (PRRs) that may
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22064Figure 1. TRIF acts as a negative regulator of rEA-induced MyD88-dependent activation of dendritic cells in vivo. C57BL/6 WT (N=3–
4), MyD88-KO (N=3), TRIF-KO (N=3–4), and MyD88/TRIF-DKO (N=4) mice were injected with 100 ng of rEA. Splenocytes were harvested at 6 hpi,
processed, stained for expression of surface markers, and FACS sorted as described in Materials and Methods. All genotype mock-injected mice
(N=2–3) were included in analysis. One of two representative experiments is shown. Separate sets of WT mice were utilized for comparison with each
knockout genotype. Activation of CD11c
+, CD19
2, and CD3
2 DCs is shown. The bars represent Mean 6 SEM. Statistical analysis was completed using
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cell types are primarily responsible for mediating rEA-triggered
responses in vivo.
MyD88 and TRIF are two adaptor proteins which primarily
mediate the signaling derived from activation of many pattern
recognition receptors (PRRs), including TLRs [6]. We have
investigated if rEA requires either of these two proteins to trigger
immune responses in vivo, and have found that all rEA-triggered
immune responses are dependent on MyD88 functionality
(including the rapid activation of DCs, macrophages, NK, NKT,
T and B cells, the induction of pro-inflammatory cytokine/
chemokine releases, as well as Erk1/2 phosphorylation). Surpris-
ingly, we discovered that functional TRIF protein acts to suppress
rEA induction of these same responses; thereby unveiling a novel
inhibitory role for TRIF during rEA mediated signaling. We also
present evidence that TRIF may similarly suppress TLR
activations by other known TLR ligands. Together the findings
highlight the complexities underlying adjuvant activation of the
innate immune system, as well suggests that simple notions of
augmenting or modifying adjuvant activity by use of TLR system
agonists or antagonists may be complicated by these complex
molecular mechanisms.
Results
TRIF acts as a negative regulator of rEA-induced
MyD88-dependent activation of dendritic cells and
macrophages in vivo
The purpose of this study was to identify the impact of rEA
stimulation on host immune systems, to define important cell types
that respond to or modulate rEA-driven activation, and to identify
signaling pathways responsible for activation of the immune
system in response to rEA. To investigate this, C57BL/6 mice
were each IP injected with 100 ng of purified, rEA protein.
Splenocytes were harvested at 6 hpi and flow cytometry was
performed as detailed in Materials and Methods. We identified
that activation of murine DCs (CD11c
+, CD19
2, CD3
2)i n
response to rEA was completely dependent on the presence of full
MyD88 functionality. Specifically, we found significant increases
in the percent of CD40+, CD80+ and CD86+ DCs (as well as
induction of the expression of these molecules per cell as measured
by Mean Fluorescent Intensity [MFI]) in rEA treated wild type
(WT) mice, but no such increases were observed in rEA treated
MyD88 knockout (KO) or MyD88/TRIF double knockout
(DKO) mice, each as compared to mock-injected animals
(Figures 1, 2 and Figures S1, S2). Surprisingly, we detected
significant (p,0.001) increases in DC activation after identical rEA
treatments of TRIF-KO mice (as compared to WT mice), as
measured by CD40, CD80 and CD86 surface staining. Further-
more, the amount of CD86 expression per cell was significantly
(p,0.001) increased in rEA treated TRIF-KO mice, as compared
to rEA treated WT mice (Figures 1, 2 and Figures S1, S2). rEA
stimulation also increased the percent of MHC-II presenting DCs
in WT and TRIF-KO mice, increases that were not seen in the
rEA-treated MyD88-KO or the MyD88/TRIF-DKO mice. The
DCs from rEA-treated TRIF-KO mice also had significantly
(p,0.05) higher MHC-II surface expression levels as compared to
rEA treated WT mice (Figure 1).
rEA-mediated activation of splenic macrophages (CD11b
+,
CD19
2, CD3
2) was also completely dependent on MyD88, as
confirmed by lack of macrophage activation in response to rEA
stimulation in the MyD88-KO or the MyD88/TRIF-DKO mice.
In contrast, WT mice injected with rEA experienced a dramatic
increase in the levels of CD80, CD86, and MHC-II, on the surface
of splenic macrophages (MFI), as well as in the percent of
macrophages, expressing the CD40, CD80, and CD86 activation
markers. Similar to observations in DCs, macrophages derived
from rEA-treated TRIF-KO mice were activated to levels that
were significantly higher than levels measured in WT mice treated
with rEA. Not only were the amounts of CD40-expressing
macrophages increased, but also both the percentages of CD80
and CD86 expressing macrophages (p,0.01) and amount of these
markers per cell (MFI, p,0.05) were significantly increased in rEA
treated TRIF-KO mice as compared to rEA-treated wild type
mice, (p,0.05) (Figures S3, S4, S5). These experiments unveiled
an important, not previously described, role of TRIF as a
suppressor of rEA-induced TLR/MyD88 signaling in DCs and
macrophages in vivo.
Interestingly, we found that baseline levels of MHC-II
expression on splenic DCs were significantly increased in
untreated, MyD88-KO and MyD88/TRIF-DKO mice (amount
of MHCII per cell, p,0.01, Figure 2) as compared to untreated
WT mice or untreated TRIF-KO mice (Figures 1, 2 and Figures
S3, S4). Additionally, the MyD88/TRIF-DKO mice also had
higher baseline levels of CD40 expression in DCs (Figure 2). This
phenomenon was not unexpected, as we had previously noted
increased baseline levels of the MHCII b-chain (three-fold higher)
in MyD88-KO mice, as confirmed by microarray transcriptome
analysis and flow cytometry based analyses ([15] and data not
shown). Potentially, these baseline changes may be due to lack of
presence of these adaptors during normal mouse development.
TRIF negatively regulates rEA-mediated activation of NK,
NKT, T and B cells in vivo
The unexpected result of TRIF being a negative regulator of
rEA-triggered activation of DCs and macrophages, prompted us to
evaluate if TRIF reduces rEA-induced activation of other
important immune cells, including effector NK cells, as well as
NKT, T and B cells. We have previously shown that rEA protein
activates splenic and hepatic NK and NKT cells within 6 hours
post-injection in WT mice [11]. In this study, rEA injections into
MyD88-KO and MyD88/TRIF-DKO mice yielded only baseline
activation levels of CD69
+ NK, NKT, T and B cells. This
contrasted with a significant activation of these same cell types in
WT mice treated with rEA protein (Figure 3 and Figures S6, S7).
Similarly, the amount of IFNc production from NK and NKT
cells was not increased in the MyD88-KO or the MyD88/TRIF-
DKO mice in response to rEA, whereas WT mice had
dramatically increased numbers of IFNc secreting NK (from 1%
to 20–30%) and NKT (from 1% to 2–5%) cells. In contrast, rEA
treatment of TRIF-KO mice revealed significant increases in the
number of IFNc producing NK cells (p,0.05), the amount of
CD69 expression per NK cell (MFI, p,0.01), the number of cells
(p,0.05) and amount (p,0.05) of IFNc-production from NKT
cells, the number of cells (p,0.01) and amount (p,0.01) of CD69
expression from T cells, and the number of B cells expressing
CD69 (p,0.01); all in comparison to rEA-treated WT mice
(Figure 3 and Figures S6, S7). Note, rEA stimulation significantly
increased the number of CD69-expressing B cells in WT and
a two tailed homoscedastic Student’s t-tests. *, ** - Indicate values statistically different from those in mock injected animals (of the same genotype),
p,0.05, p,0.001 respectively.
doi:10.1371/journal.pone.0022064.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22064Figure 2. TRIF acts as a negative regulator of rEA-induced MyD88-dependent activation of dendritic cells in vivo (MFI). C57BL/6 WT
(N=3–4), MyD88-KO (N=3), TRIF-KO (N=3–4), and MyD88/TRIF-DKO (N=4) mice were injected with 100 ng of rEA. Splenocytes were harvested at
6 hpi, processed, stained for expression of surface markers, and FACS sorted as described in Materials and Methods. All genotype mock-injected mice
(N=2–3) were included in analysis. One of two representative experiments is shown. Separate sets of WT mice were utilized for comparison with each
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expression per cell (Figure S6).
Within 6 hours of administration, rEA protein triggers signif-
icant production of pro-inflammatory cytokines and chemokines in
mice. Specifically, circulating levels of IL12p70, IL6, TNFa, IFNc,
IL2 were markedly elevated in rEA-treated mice [8,9]. Purified
murine DCs exposed to 0.2 ng/ml of rEA were shown to release
significant amounts of IL12p70, IL6, and IL2 [8]. We confirmed
and extended the observation that rEA triggers the release of a
wide spectrum of pro-inflammatory cytokines and chemokines,
including IL6, IL12p40, IL12p70, GCSF, IFNc, IL2, IL1a, IL1b,
IL10, IL13, GMCSF, KC, MCP1, MIP1a, MIP1b, RANTES,
and TNFa. This effect was however, completely dependent on
MyD88 given that all of these analytes were induced in rEA-
treated WT, but not in rEA-treated MyD88-KO or MyD88/
TRIF-DKO mice (Figure 4). Again, paralleling our previous
results, the release of all of these cytokines and chemokines was
significantly increased in rEA-treated TRIF-KO mice, and the
majority of these analytes were elevated to levels that were
significantly higher than levels measured in rEA-treated WT mice.
In particular, IL6 was induced to ,3 fold (p,0.001) higher levels
and IL12p40, GCSF, and IFNc were induced to over 2 fold
(p,0.001) higher levels when comparing rEA-treated TRIF-KO
mice to rEA-treated WT mice. Moreover, IL12p70, IL2, IL1a,
IL1b, and MIP1a were also produced at significantly higher levels
in rEA-treated TRIF-KO mice as compared to rEA treated WT
mice (Figure 4).
Dendritic cells are a major cell type mediating rEA
responses
It is known that many of the rEA induced cytokines and
chemokines are released by DCs (Figure 4) [16]. For that reason,
we purified CD11c
+ DCs from WT, MyD88-KO, TRIF-KO, and
MyD88/TRIF-DKO mice, and then stimulated the cells ex vivo
with escalating amounts of rEA protein. Utilizing an IL12p70
specific ELISA, we confirmed that in response to rEA, DC
production of this cytokine was completely dependent upon
functional MyD88 (Figure 5A). The minimal rEA dose in which
WT mouse-derived DCs produced significant amounts of IL12p70
was found to be 100 pg/mL, whereas TRIF-KO mouse-derived
DCs only required a 10 pg/mL dose (10 fold less) for significant
IL12p70 release. In an overall comparison to WT mouse derived
DCs, TRIF-KO mouse derived DCs had a significantly higher
production of IL12p70 in response to rEA. The most dramatic
difference between these two groups was noted when DCs were
stimulated with a 0.2 ng/ml dose of rEA, which caused
,1300 pg/ml of IL12p70 to be released from DCs derived from
TRIF-KO mice as compared to ,600 pg/ml from DCs derived
from WT mice (p,0.01) (Figure 5A.)
We have verified our ELISA-based data for IL12p70 indepen-
dently, by Bioplex bead array. Again, we confirmed that MyD88-
KO and the MyD88/TRIF-DKO mouse derived DCs each
respectively failed to produce significant levels of pro-inflamma-
tory cytokines and chemokines in response to rEA stimulation.
Interestingly, we also confirmed that these rEA mediated DC
responses were also partially suppressed by TRIF, as, IL2, IL6,
IL12p40, IL12p70, IL1a, IL1b, and MIP1a were released to
significantly (p,0.05) higher levels in rEA-treated DCs derived
from TRIF-KO mice, as compared to those derived from WT
mice (Figure 5B).
TRIF negatively regulates cytokine production by DCs,
triggered by several common TLR agonists
To more fully investigate if TRIF suppressive effects were rEA-
specific or a more global phenomenon, we have specifically
stimulated CD11c
+ DCs, isolated from WT, TRIF-KO, MyD88-
KO or MyD88/TRIF-DKO mice with various common TLR4,
TLR7/8, an TLR9 agonists. Specifically, LPS, R848 and
ODN2006 were utilized in these experiments. All of these TLR
agonists were able to induce pro-inflammatory cytokine produc-
tion after administration to DCs, as compared to unstimulated
DCs, all derived from WT mice. Importantly, however, DCs
derived from TRIF-KO mice had dramatically higher levels of
secretion of pleiotropic pro-inflammatory cytokines, when stimu-
lated with these same TLR agonists (Figure 6AB). Specifically,
ODN2006 stimulation resulted in significantly higher IL6,
IL12p40, IL12p70 and MIP1a levels; LPS stimulation significantly
increased IL1a, IL3, IL6, IL12p70 levels; R848 treatment resulted
in significantly higher production of IL1a, IL1b, IL6, and MIP1a;
in DCs, derived from TRIF-KO mice as compared to DCs
derived from WT mice, as tested both by ELISA (Figure 6A) and
Bioplex analysis (Figure 6B and data not shown). DCs derived
from MyD88-KO or MyD88/TRIF-DKO mice did not show any
significant cytokine activations when stimulated with any of these
TLR agonists (data not shown). Interestingly, lack of the TRIF
adaptor protein resulted in up to 2 fold increases in cytokine
production from DCs, when stimulated with LPS or ODN2006
(i.e. IL12p70), indicating that the suppressive role of TRIF in this
cell type might be immunologically significant.
rEA-triggered Erk1/2 phosphorylation is MyD88
dependent
Extensive past research has demonstrated that the major
signaling pathways activated downstream of TLR adaptor proteins
(e.g. MyD88, TRIF) are the NFkB and MAPK pathways [17].
Along with many other biological roles, these pathways promote
production of cytokines and chemokines as well as proliferation,
maturation, and development of various immune cells. To identify
which of the several signaling pathways may be activated in
response to rEA in vivo, we IP injected WT or MyD88-KO mice
with 100 ng of rEA, then collected spleen and liver tissues at
various time points (0–120 minutes) post-injection. We found that
rEA-triggered Erk1/2 phosphorylation was MyD88 dependent, as
confirmed by increased Erk1/2 phosphorylation in rEA-treated
WT mice, but not in the MyD88-KO mice (Figure 7).
Discussion
The ideal adjuvant (from Latin ‘‘adjuvare’’, meaning ‘‘to
enhance’’) is an agent that is capable of dramatically enhancing
both cellular and humoral adaptive immune responses to co-
administered antigens, thereby providing more efficient and long-
term protection against specific pathogens. Aluminum salts,
discovered to be potent adjuvants in 1920s, remained the only
FDA approved adjuvant for many decades and still represent one
of the few in clinical use. A barrier in adjuvant research has been
that the mechanism of action of many adjuvants remained poorly
knockout genotype. Mean Fluorescent Intensity (MFI) is shown and is indicative of amount of analyte per cell. The bars represent Mean 6 SEM.
Statistical analysis was completed using two-tailed homoscedastic Student’s t-tests. *, ** - Indicate values statistically different from those in mock-
injected animals (of the same genotype), p,0.05, p,0.001 respectively.
doi:10.1371/journal.pone.0022064.g002
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emulsion MF59 promote recruitment and increase antigen uptake
by APCs, induce cytokine and chemokine secretions, and the
expression of adhesion molecules involved in migration of
leukocytes [18,19]. More recently it has also been confirmed that
alum and squalene based adjuvants may use the NOD-like
receptor protein 3 (NLRP3) inflammasome pathway to activate
the innate immune system [20,21].
The Eimeria tenella derived protein, was isolated from bovine
small intestinal extracts and was shown to have remarkable anti-
cancer activity and be a potent stimulator of innate immune
responses in various mouse models in vitro and in vivo [8,22,23].
The rEA protein, we believe, might possess all the properties of an
ideal immunologic adjuvant, as it can be fairly inexpensive to
produce, is extremely stable and can be stored for long periods of
time (over 24 month, data not shown) without losing activity. The
rEA has been shown to be safe and very well-tolerated in human
clinical trials [13]. In mice, rEA augments activation of the innate
immune system, presumably by activating PRRs (TLRs and/or
possibly others) and thereby increasing adaptive immune responses
to co-administered antigens [11,12]. It has been suggested that
TLR11 is involved in rEA signaling [9], a notion that is primarily
based on high sequence homology (67%) between rEA and T.
gondii profilin-like protein, the latter being the only confirmed
ligand for TLR11 [14].
In this study we confirmed that administration into mice, or
direct exposure of immune cells to rEA protein results in (1)
activation of important immune cell types (DCs, macrophages,
NK, NKT, B and T cells), including (2) pro-inflammatory
cytokines/chemokines release, both globally and specifically by
DCs, and highly robust IFNc production by NK cells, and (3)
Erk1/2 phosphorylation. Therefore, we showed that rEA,
similarly to other TLR-agonist-based adjuvants, activated an
innate immune profile that resulted in robust activation of innate
immune cells and induced multiple cytokines/chemokine path-
ways. Our results also confirmed that these responses are
completely dependent upon MyD88, as genetic knockout of this
adaptor protein results in complete ablation of these responses
both in vitro and in vivo.
When we similarly investigated the role of TRIF, the other
major TLR adaptor protein, we encountered unexpected results.
Specifically, TRIF-KO mice showed dramatic increases, in immune
cell activation and other rEA triggered responses, when compared
to rEA treated WT mice. Specifically, we found that IL6,
IL12p40, IL2, IL1a, IL1b, and MIP1a production was induced
by rEA treatment in TRIF-KO mice in vivo and in DCs derived
from these mice in vitro to significantly higher levels as compared to
similar assays performed in rEA-treated WT mice. Note, that rEA
mediated induction of IL12p70, a cytokine abundantly produced
by DCs that activates NK cells, was also found to be negatively
regulated by TRIF after exposure to rEA [16,24].
Therefore, in response to rEA-mediated stimulation, TRIF acts
as a suppressor of the rEA-induced (MyD88-dependent) activation
of DCs, macrophages, NK, NKT, T, and B cells in vivo. Despite
the lack of TRIF activity in MyD88/TRIF-DKO mice, rEA
responses were still ablated which indicates that in the absence of
MyD88, TRIF cannot carry out its suppressive activity. Since the
lack of TRIF protein does not rescue the phenotype in MyD88/
TRIF-DKO mice, this confirms an essential role of MyD88 in
mediating these responses and suggests that TRIF protein acts as a
suppressor downstream of MyD88 and/or MyD88 and TRIF
adaptor molecules orchestrating the induction of pro-inflammato-
ry immune responses following rEA injection.
Numerous studies have described important roles for TRIF as a
TLR system adaptor protein that acts to enhance TLR-based
signaling (predominantly when TLR3 and TLR4 ligands are
interrogated, thereby promoting antimicrobial responses
[6,17,25,26]. Specifically, TRIF-KO mice showed dramatically
impaired lung clearance of Pseudomonas aeruginosa infections; a
response that is correlated with blunted cytokine induction (e.g.
RANTES, IL1b, MIP2) and reduced NFkB activation present in
both alveolar and peritoneal macrophages from these mice [27].
Lack of TRIF protein also results in reduced induction of antigen
specific humoral and cellular immune responses in other models
[28]. Specifically, T cells derived from TRIF-KO mice had
dramatically reduced IFNc production and CXCR3 expression
upon antigen/LPS treatment as compared to WT mice [29]. In
DCs, TRIF functionality was confirmed to be important for
upregulation of CD40 and CD86 co-stimulatory molecules [30].
Moreover, TRIF protein along with IPS1 (RIGI/Mda5 pathway
protein) are key adaptors in mediating PolyIC-triggered adjuvant
effects [28].
Conversely, there is very little data available that describes
suppressive roles of TRIF protein on TLR/PRR signaling.
Specifically, we have previously demonstrated that a lack of
functional TRIF protein results in increased transgene (e.g. b-Gal)
specific IgG titers in mice injected with Ad5-LacZ, suggesting that
TRIF may act as a negative regulator of Ad-mediated antibody
responses in mice [31]. Other researchers have demonstrated that
TRIF has an inhibitory role in TLR5-mediated responses through
induction of TLR5 degradation [32]. This phenomenon may not
be limited to TLR5, as it has been suggested that TRIF can also
induce degradation of other TLRs, including TLRs 3, 6, 7, 8, 9,
and 10 [32]. To determine if the suppressive role of TRIF in DCs
is more global than previously considered, we have stimulated
isolated DCs with TLR4 (LPS), TLR7/8 (R848) or TLR9
(ODN2006) agonists and found that the presence of the TRIF
adaptor protein significantly suppresses release of pleiotropic pro-
inflammatory cytokines by DCs in response to these agonists.
These studies suggest that suppressive activities of TRIF, in regard
to pathogen-induced innate immune responses, may be more
prevalent than currently appreciated.
Activation of pro-inflammatory cytokines/chemokines is a
critical step during DC activation/maturation. It has been
suggested that TRIF may be required for inducing immunological
tolerance by augmenting IL10 production [33,34]. We found,
however, that in rEA (or other TLR agonist) treated TRIF-KO
mice, amounts of IL10 (both in plasma and in isolated DCs) were
indistinguishable to identically (rEA) treated WT mice.
To successfully bridge DC activation to induction of substantial
adaptive immune responses (e.g. T cell activation), it is essential to have
induction of co-stimulatory molecules such as CD40, CD80, and
Figure 3. TRIF acts as a negative regulator of rEA-induced MyD88-dependent activation of NK, NKT, T, and B cells in vivo. C57BL/6 WT
(N=3–4), MyD88-KO (N=3), TRIF-KO (N=3–4), and MyD88/TRIF-DKO (N=4) mice were injected with 100 ng of rEA. Splenocytes were harvested at
6 hpi, processed, stained for expression of surface markers (intracellular staining was performed for IFNc), and FACS sorted as described in Materials
and Methods. All genotype mock-injected mice (N=2–3) were included in analysis. Separate sets of WT mice were utilized for comparison with each
knockout genotype. Activation of NK, NKT, T, and B cells is shown. The bars represent Mean 6 SEM. Statistical analysis was completed using a two
tailed homoscedastic Student’s t-tests. *, ** - Indicate values statistically different from those in mock injected animals (of the same genotype),
p,0.05, p,0.001 respectively.
doi:10.1371/journal.pone.0022064.g003
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administration of rEA results in robust maturation of DCs, as
evidenced by not only increased expression of co-stimulatory molecules
on these DCs, but also that rEA increased cytokines and chemokine
production. While these responses were completely abrogated in rEA-
treated MyD88-KO mice, most of them were dramatically enhanced
i nT R I F - K Om i c ew h e nc o m p a r e dt or E At r e a t e dW Tm i c e .
From this information, we are proposing a model of rEA
signaling in DCs (see Figure 8). The rEA protein likely interacts
with a PRR, (likely TLR11 in mice, unknown in humans [9]), that
senses rEA. The MyD88 adaptor protein gets recruited which
allows MAP kinases downstream of MyD88 to become activated
(pErk1/2, p38). pErk1/2 is capable of activating various
transcription factors (e.g. AP1) which further activates pro-
inflammatory genes, including those of pro-inflammatory cyto-
kines/chemokines [17,26,29,35]. In contrast, functional TRIF
protein acts as a negative regulator of the rEA-induced signaling.
As a result of TRIF’s inhibitory effects, DCs have a reduction in
surface expression of maturation markers, as well mitigated release
of pro-inflammatory cytokines/chemokines [16].
Figure 4. TRIF negatively regulates rEA-mediated MyD88 dependent activation of pro-inflammatory cytokines and chemokines in
vivo. C57BL/6 WT (N=9), MyD88-KO (N=3), TRIF-KO (N=3–4), and MyD88/TRIF-DKO (N=4) mice were injected with 100 ng of rEA. Plasma samples
were collected at 6 hpi and were analyzed using a multiplexed bead array based quantitative system. All genotype mock-injected mice (N=2–3) were
included in analysis. One of two representative experiments is shown. Statistical analysis was completed using a one-way ANOVA with a Student-
Newman-Keuls post-hoc test. The bars represent Mean 6 SD. *, ** - Indicate plasma cytokine values that are statistically different from those in mock
injected animals, p,0.05, p,0.001 respectively. No significant differences between mock-injected animals of different genotypes were detected. No
significant activation of cytokines was observed in MyD88-KO and MyD88/TRIF-DKO animals.
doi:10.1371/journal.pone.0022064.g004
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22064Figure 5. TRIF negatively regulates rEA-mediated MyD88 dependent activation of pro-inflammatory cytokines and chemokines in
dendritic cells. (A) CD11c
+ dendritic cells were isolated from C57BL/6 WT (N=2), MyD88-KO (N=2), TRIF-KO (N=2), and MyD88/TRIF-DKO (N=2)
mice, in vitro stimulated with rEA, then used to perform a IL12p70 ELISA as described in Materials and Methods. One (of three) representative
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22064In conclusion, our murine models have shown that rEA
activates multiple immune cell types, stimulates pro-inflammatory
cytokine/chemokine release, and triggers the MAPK pathway in a
MyD88 dependent manner. We have also confirmed that DCs are
the main subset of innate immune cells that mediate rEA-triggered
responses, thus justifying future studies on isolated DCs and the
potential use of rEA adjuvant in a DC-vaccine setting [36].
Importantly, our studies of rEA unveiled a suppressive activity to
the TRIF adaptor protein. This clearly justifies future testing of
specific TRIF inhibitors or knockdown models prior to rEA/
antigen administration as a means to further enhance induction of
antigen specific adaptive immune responses. Whether TRIF acts
to negatively regulate other adjuvants or TLR-mediated activa-
tions is a question that will require future investigations. The latter,
however, highlights the complexities of TLR adaptor functions,
and should temper efforts that target these proteins with agonists
or antagonists, as the end result of such interventions may run
counter to hoped for outcomes, and could be detrimental in some
situations [37].
Materials and Methods
Animal Procedures
All animal procedures were reviewed and approved by the
Michigan State University ORCBS and IACUC. Care for mice
was provided in accordance with PHS and AAALAC standards
(ID number: A3955-01). Adult male C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor, ME).
MyD88-KO and TRIF-KO mice were kindly provided by Dr.
Shizuo Akira. MyD88/TRIF-DKO mice were bred at Michigan
State University. Intraperitoneal (IP) injection of animals (2–4
months in age) consisted of 100 ml phosphate-buffered saline
solution (PBS, pH 7.4) containing 100 ng rEA protein from
Eimeria tenella as previously described [8,11]. rEA protein
purification was performed as previously described [8] with minor
modifications described [11]. Plasma and tissue samples were
obtained and processed at the indicated times post-injection as
previously described [11]. Importantly, IP route of rEA admin-
istration was confirmed to be more efficient that other widely used
routes for adjuvant injection, such as intranasal or subcutaneous
[7,8]. To study rEA-triggered activation of immune cells by flow
cytometry and bead array methods, plasma and spleen tissues were
harvested at 6 hours post injection (hpi), whereas for studies
measuring activation of signaling pathways the spleen and liver
tissues were harvested at 0, 20, 40, 60, 90, and 120 minutes post-
rEA injection.
Cytokine and chemokine analysis
A mouse 23-plex multiplex based assay was used to determine
the indicated cytokine/chemokine concentrations in the plasma
collected in vivo or the media collected from cultured DCs per the
manufacturer’s instructions (Bio-Rad, Hercules, CA) via Luminex
100 technology (Luminex, Austin, TX) as previously described
[38].
Isolation of Splenocytes
Splenocytes from individual mice were harvested and processed
by physically disrupting and facilitating passage of splenic tissue
through a 40 mm sieve, followed by induction of RBC lysis by
using 2 ml of ACK lysis buffer (Invitrogen, Carlsbad, CA) per
homogenized spleen. Splenocytes were subsequently washed two
times with RPMI medium 1640 (Invitrogen, Carlsbad, CA)
supplemented with 10% FBS, 2 mM L-glutamine, and 1% PSF
(penicillin, streptomycin, fungizone), then resuspended and
counted.
Cell staining and flow cytometry
Splenocyte preparations were evaluated for the presence of DC,
macrophages, NK, NKT, T, and B cell activation/maturation
markers as previously described [11,39]. 1610
6 cells were stained
with combinations of the following antibodies: APC-CD3,
PerCpCy5.5-CD19, PE-Cy7-NK1.1, and PE-CD69 (all 4 mg/ml)
or PECy7-Cd11c, APCCy7-CD11b, APC-CD80, Pacific Blue-
CD86, Alexa Fluor700-MHCII, FITC-CD40, and PerCpCy5.5-
CD3/CD19/NK1.1 (dump channel) (all 4 mg/ml) (BD Bioscienc-
es, San Diego, CA). Cells were incubated on ice with the
appropriate antibodies in 2.4G2 hybridoma cell supernatant for
30 minutes, then washed and sorted using a BD LSR II
instrument. For intracellular staining, 2610
6 splenocytes were
incubated with Brefeldin A (1 mg/ml) in DMEM with 10%FBS/
16PSF for 4 hours at 37uC. Following incubation, splenocytes
were washed two times with FACS buffer, incubated for
15 minutes with purified rat anti-mouse CD16/CD32 Fcc block
(BD Biosciences, San Diego, CA), surface stained with CD3-APC
and NK1.1-PECy7 (8 mg/ml) for 30 minutes at 4u C, washed with
FACS buffer, fixed with 2% formaldehyde (Polysciences, War-
rington, PA) for 20 minutes on ice, permeabilized with 0.5%
Saponin (Sigma-Aldrich, St. Louis, MO) for 20 minutes at room
temperature, and incubated on ice with IFNc-FITC (8 mg/ml) for
2 hours. Samples were analyzed on a BD LSR II instrument using
FlowJo software (Tree Star, San Carlos, CA, USA).
Western blotting
Spleen and liver tissues were homogenized in lysis buffer
(20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl)
containing 1% Triton X-100 with protease inhibitors. Homoge-
nized tissues were then centrifuged at maximum speed (13,0006G)
for 10 min at 4uC, after which the protein concentration of the
supernatant determined using BCA method. Western blotting for
pErk1/2 and Erk2 was performed as previously described
[40,41,42]. Equivalent concentrations of protein samples were
run on polyacrylamide gels and transferred onto nitrocellulose
membranes. Blots were then probed with fluorescent antibodies as
previously described, which included antibodies against pErk1/2
experiments is shown. The bars represent Mean 6 SD. Statistical analysis was completed using a two-way ANOVA with a Bonferroni post-hoc test
(genotypes6rEA treatments). *, ** - Indicate values that are statistically different from those in unstimulated DCs (for the same genotype), p,0.05,
p,0.001 respectively. #, ## - Indicate values statistically different from those in WT DCs (for the same rEA dose), p,0.05, p,0.01 respectively. No
significant differences between mock-injected animals of different genotypes were detected. No significant activation of IL12p70 was observed in
MyD88-KO and MyD88/TRIF-DKO DCs. (B) DC culture media was collected at 18 hours post-rEA stimulation (0.2 ng/ml) and was analyzed for
cytokines/chemokines levels using a multiplexed bead array based quantitative system. Statistical analysis was completed using a one-way ANOVA
with a Student-Newman-Keuls post-hoc test. The bars represent Mean 6 SD. *, ** - Indicate cytokine values that are statistically different from those
in mock injected animals, p,0.05, p,0.001 respectively. No significant differences between mock-injected animals of different genotypes were
detected. No significant activation of pro-inflammatory cytokines was observed in MyD88-KO and MyD88/TRIF-DKO animals (only anti-inflammatory
IL10 cytokine was induced in MyD88-KO mice).
doi:10.1371/journal.pone.0022064.g005
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22064Figure 6. TRIF negatively regulates cytokine production by DCs, triggered by several common TLR agonists. (A) CD11c
+ dendritic cells
were isolated from C57BL/6 WT (N=3), MyD88-KO (N=3), TRIF-KO (N=3), and MyD88/TRIF-DKO (N=3) mice, in vitro stimulated with various TLR
agonists, and used to perform a IL12p70 ELISA as described in Materials and Methods. The bars represent Mean 6 SEM. Statistical analysis was
completed using a one-way ANOVA with Student-Newman-Keuls post-hoc test. ** - Indicate values that are statistically different from those in
unstimulated DCs (for the same genotype), p,0.001. No significant differences between mock-injected animals of different genotypes were
detected. No significant activation of IL12p70 was observed in MyD88-KO and MyD88/TRIF-DKO DCs. (B) DC culture media was collected at 15 hours
post stimulation with various TLR agonists (rEA, LPS, ODN2006) and was analyzed for cytokines/chemokines levels using a multiplexed bead array
based quantitative system. Statistical analysis was completed using a one-way ANOVA with a Student-Newman-Keuls post-hoc test. The bars
represent Mean 6 SD. *, ** - Indicate cytokine values that are statistically different from those in mock injected animals, p,0.05, p,0.001
respectively.
doi:10.1371/journal.pone.0022064.g006
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PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e22064(Cell Signaling, Inc., Boston, MA) and Erk2 (Santa Cruz
Biotechnologies, Santa Cruz, CA). Blots were scanned and bands
were quantified using Licor’s Odyssey scanner [41]. For data
analysis, the fluorescence of pErk1/2 bands was normalized to
Erk2 bands prior to quantification.
Mouse Dendritic Cells isolation and mIL12p70 ELISA
An in vitro bioassay originally developed to monitor rEA activity
during its purification and production, as well as provide some
insight into the mechanism of action of rEA, was previously
described [8]. The assay is based upon monitoring the release of
mIL12(p70) from mouse DCs as an indicator of rEA-induced DC
activation. Mouse DCs (CD11c
+ splenocytes) were isolated from
C57BL/6 WT, MyD88-KO, TRIF-KO, or MyD88/TRIF-DKO
mice using the magnetic assisted cell separation (MACS) system
(Miltenyi Biotech, Auburn, CA) utilizing the established protocols
from the manufacturer and previously described [8]. DC sorting
via flow cytometry resulted in .95% pure CD11c positive cell
population (Figure S8). The viability of recovered DCs was ,90%,
as measured by trypan blue viability staining.
Figure 7. rEA-triggered Erk1/2 phosphorylation is MyD88 dependent. C57BL/6 WT or MyD88-KO mice were injected with 100 ng of rEA.
Spleen (A) and liver (B) tissues were collected at the indicated time points and processed as described in Materials and Methods. p-Erk1/2 and Erk2
levels were determined by Western blot analysis using LI-COR Odyssey. To control for loading, quantification was performed after normalizing the
pErk1/2 to Erk2 levels. Three independent experiments representative of this data are shown. (C) Representative blots: spleen (top), liver (bottom).
doi:10.1371/journal.pone.0022064.g007
Figure 8. TRIF acts as a negative regulator of rEA-induced signaling and downstream responses in DCs: model of action. rEA is a
protein derived from Eimeria tenella [8,11] and is highly homologous to Toxoplasma gondii profilin-like protein [14]. T. gondii has been shown to
signal, at least in part, through TLR11; therefore, it is likely that TLR11 is one of the main pattern recognition receptors (PRRs) utilized by rEA. We have
shown that rEA-triggered responses in vivo are completely dependent on MyD88. MAP kinases consequently become activated downstream of
MyD88. Importantly, functional TRIF protein inhibited rEA-mediated signaling. DCs are a major cell type in mediating rEA responses and, under TRIF’s
inhibitory effects, have mitigated induction of surface expression of maturation markers and stunted release of pro-inflammatory cytokines/
chemokines. Release of these molecules is critical for rapid amplification of immune responses and is mediated by autocrine and paracrine signaling
[16]. We have confirmed that TRIF protein reduces release of pro-inflammatory cytokines/chemokines in response to rEA, resulting in reduced
activation of NK, NKT, T, and B cells as well as reduced IFNc production by NK cells.
doi:10.1371/journal.pone.0022064.g008
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+ cells were seeded at a density of 0.3610
5 cells
per well into 96-well plates in 200 ml/well complete medium. The
complete medium consisted of DMEM/F12 supplemented with
10% FCS, gentamicin (10 mg/ml), recombinant mouse GMCSF
(1 ng/ml), recombinant mouse IL4 (1 ng/ml), recombinant mouse
IFNc (3 ng/ml), and an agonistic anti mouse CD40 antibody
(0.5 mg/ml) (R&D Systems, Minneapolis, MN). This synergistic
combination of cytokines has no significant effect on mouse IL12
release, but dramatically enhances the inducing effects of rEA on
mouse IL12 release [8]. Mouse DCs were stimulated with rEA
(10
26–10
1 ng/ml) overnight (,18 hours) at 37u Ci n5 %C O 2 and
95% ambient air. To study the specificity of TRIF inhibitory
effects in DCs, various toll-like receptor agonists were added to
mouse DCs, using the following concentrations: rEA (Barros
Research Institute, Holt, MI, 100 ng/ml); E. coli 0111.B4 LPS
(20 mg/ml); R848 (0.5 mg/ml) and ODN2006 (2.5 mM). LPS,
R848 and ODN2006 (TLR4, TLR7/8 and TLR9 agonists
respectively) were purchased from InvivoGen, San Diego, CA,
reconstituted with endotoxin-free water and diluted in culture
media (DMEM/F12+10% FCS). Following incubation, culture
medium was analyzed for mouse IL12p70 levels using an ELISA
kit and following its enclosed instructions (R&D Systems,
Minneapolis, MN) or for 23 mouse cytokines/chemokines using
multiplex system (Bio-Rad, Hercules, CA).
Statistical analysis
Statistically significant differences in immune cells activation assays
were determined using two-tailed homoscedastic Student’s t-tests to
compare rEA mediated responses in WT mice against each
individual knockout genotype in independent experiments (p
value,0.05). Statistically significant differences in plasma or media
cytokine levels were determined using a one-way ANOVA with a
Student-Newman-Keuls post-hoc test (p value,0.05). Furthermore,
a two-way ANOVA with a Bonferroni post-hoc test was used to
analyze the levels of IL12p70 in media from cultured DCs
(genotype6rEA treatments) that were derived from WT, MyD88-
KO, TRIF-KO or MyD88/TRIF-DKO mice and treated with
several escalating concentrations of rEA. Graphs in this paper are
presented as mean of the average 6 SEM, unless otherwise specified.
GraphPad Prism software was utilized for statistical analysis.
Supporting Information
Figure S1 TRIF acts as a negative regulator of rEA-
induced MyD88-dependent activation of dendritic cells
in vivo. Representative histograms are illustrated on this figure.
(TIF)
Figure S2 Sorting strategy for CD11c
+ cells. Representa-
tive figure of the gating strategy for sorting CD11c+ DCs. (A)
Splenocytes were stained with CD11c-PECy7 and CD11b-APC-
Cy7 antibodies and data were generated using LSR-II cytometer.
(B) Splenocytes were stained with CD11c-PECy7 and
PerCPCy5.5 conjugated antibodies for CD3, NK1.1, and CD19
to exclude T-, NK-, and B-cells from the analysis.
(TIF)
Figure S3 TRIF acts as a negative regulator of rEA-
induced MyD88-dependent activation of macrophages in
vivo. C57BL/6 WT (N=3–4), MyD88-KO (N=3), TRIF-KO
(N=3–4), and MyD88/TRIF-DKO (N=4) mice were injected
with 100 ng of rEA. Splenocytes were harvested at 6 hpi,
processed, stained for expression of surface markers, and FACS
sorted as described in Materials and Methods. All genotype mock-
injected mice (N=2–3) were included in analysis. One of two
representative experiments is shown. Separate sets of WT mice
were utilized for comparison with each knockout genotype.
Activation of CD11b
+, CD19
2, and CD3
2 macrophages is
shown. The bars represent Mean 6 SEM. Statistical analysis
was completed using a two tailed homoscedastic Student’s t-tests.
*, ** - Indicate values significantly higher (#, ## - lower) from
those in mock injected animals (of the same genotype), p,0.05,
p,0.001 respectively.
(TIF)
Figure S4 TRIF acts as a negative regulator of rEA-
induced MyD88-dependent activation of macrophages
cells in vivo. C57BL/6 WT (N=3), MyD88-KO (N=3), TRIF-
KO (N=3), and MyD88/TRIF-DKO (N=4) mice were injected
with 100 ng of rEA. Splenocytes were harvested at 6 hpi,
processed, stained for expression of surface markers, and FACS
sorted as described in Materials and Methods. All genotype mock-
injected mice (N=2–3) were included in analysis. Separate sets of
WT mice were utilized for comparison with each knockout
genotype. Mean Fluorescent Intensity (MFI) is shown and is
indicative of amount of analyte per cell. The bars represent Mean
6 SEM. Statistical analysis was completed using two-tailed
homoscedastic Student’s t-tests. *, ** - Indicate values significantly
higher (#, ## - lower) from those in mock-injected animals (of
the same genotype), p,0.05, p,0.001 respectively.
(TIF)
Figure S5 TRIF acts as a negative regulator of rEA-
induced MyD88-dependent activation of macrophages in
vivo. Representative histograms are illustrated on this figure.
(TIF)
Figure S6 TRIF acts as a negative regulator of rEA-
induced MyD88-dependent activation of NK, NKT, T,
and B cells in vivo. C57BL/6 WT (N=3), MyD88-KO (N=3),
TRIF-KO (N=3), and MyD88/TRIF-DKO (N=4) mice were
injected with 100 ng of rEA. Splenocytes were harvested at 6 hpi,
processed, stained for expression of surface markers (intracellular
staining was performed for IFNc), and FACS sorted as described
in Materials and Methods. All genotype mock-injected mice
(N=2–3) were included in analysis. Separate sets of WT mice
were utilized for comparison with each knockout genotype. Mean
Fluorescent Intensity (MFI) is shown and is indicative of amount of
analyte per cell. The bars represent Mean 6 SEM. Statistical
analysis was completed using two-tailed homoscedastic Student’s t-
tests. *, ** - Indicate values significantly higher (#, ## - lower)
from those in mock-injected animals (of the same genotype),
p,0.05, p,0.001 respectively.
(TIF)
Figure S7 TRIF acts as a negative regulator of rEA-
induced MyD88-dependent activation of NK, NKT, T,
and B cells in vivo. Representative histograms and plots are
illustrated on this figure.
(TIF)
Figure S8 Validation of CD11c+ DCs isolation. DC
sorting resulted in .95% pure CD11c positive cell population.
The viability of recovered DCs was ,90% as measured by trypan
blue viability staining.
(TIF)
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